A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B
A phase 3 trial of Elritercept run by Takeda, now recruiting.
Overview
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions is a phase 3 interventional study registered as NCT06499285 by Takeda, with 225 participants planned, started 2025-05-06. Conditions listed: Myelodysplastic Syndromes. No results are recorded here; the registry entry is the source.
Setting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
Phase
Phase 3
Sponsor
Takeda
Registry
Enrolled
225